Improving Profitability and Corporate Value Through the Development of High-Value-Added Products

「For collagen peptides, the company will continue to focus on capturing robust protein demand in North America, while further expanding the production capacity of its Indian facility, which was expanded from July 2025, from 1,150t per year to 1,800t per year starting in the fiscal year ending March 2027, with the aim of expanding sales in growth markets such as Asia.」

「• Development of new markets and products, including highly processed products • Functional research • Research and development of collagen for cell culture and biomaterials • Development of new medical-grade gelatin and collagen products」

「The group has set its long-term vision as “contributing to improving people’s QOL through collagen,” and its business strategy is to “shift from general-purpose gelatin to high-value-added collagen peptides, allocate management resources preferentially to markets expected to grow, and transform into a highly profitable company.”」

「The group has set its long-term vision as “contributing to improving people’s QOL through collagen,” and its business strategy is to “shift from general-purpose gelatin to high-value-added collagen peptides, allocate management resources preferentially to markets expected to grow, and transform into a highly profitable company.”」

「The business strategy is to shift from commodity gelatin to higher-value-added collagen peptides, allocate management resources strategically to markets with growth potential, and transform the company into a highly profitable business.」

「In June 2022, the group announced a business strategy under which its 10-year vision would be to “contribute to improving people’s QOL through collagen,” with specific measures to “shift from general-purpose gelatin to high-value-added collagen peptides, allocate management resources preferentially to markets expected to grow, and transform into a highly profitable company.”」

「In June 2022, the group announced a business strategy under which its 10-year vision would be to “contribute to improving people’s QOL through collagen,” with specific measures to “shift from general-purpose gelatin to high-value-added collagen peptides, allocate management resources preferentially to markets expected to grow, and transform into a highly profitable company.”」

「As specific measures, the company declared that it would “shift from general-purpose gelatin to high-value-added collagen peptides, allocate management resources preferentially to markets expected to grow, and transform into a highly profitable company.”」

「Under these management policies, the group worked to expand sales of high-value-added products in the priority markets of its 3 core areas: food solutions, health support, and biomedical products.」

「Under these management policies, the group worked to expand sales of high-value-added products in the priority markets of its 3 core areas: food solutions, health support, and biomedical products.」

「In light of delays in the development and sale of high-value-added products under the previous medium-term management plan, intensifying competition due to the phased elimination of tariffs, and issues associated with Japan’s super-ageing society, the company will identify priority markets in each of its 3 core areas—food solutions, health support, and biomedical products—and allocate management resources preferentially to them. Through these efforts, it aims to expand sales of high-value-added products and become a highly profitable company.」

「The group’s management policies under the medium-term management plan ending in the fiscal year ending March 2021 are as follows. …Under these management policies, the group actively pursued the development and sale of high-value-added products and new products, as well as the development of new markets, in the 3 core areas.」

「The group’s management policies under the medium-term management plan ending in the fiscal year ending March 2021 are as follows. 1. Make food solutions, health support, and biomedical products the 3 core areas. 2. Optimise the production and supply systems in Japan, Asia, and North America globally to respond to the era of free trade. 3. Promote selection and concentration, create high-value-added products and services, and transform the company into a more highly profitable business. Under these management policies, the group actively pursued the development and sale of high-value-added products and new products, as well as the development of new markets, in the 3 core areas.」

「Under these management policies, the group actively pursued research and new product development in the 3 core areas and the development of new markets.」

「The group launched a new 3-year medium-term management plan in April 2018. The group’s management policies under this plan are as follows. 1. Make food solutions, health support, and biomedical products the 3 core areas. 2. Optimise the production and supply systems in Japan, Asia, and North America globally to respond to the era of free trade. 3. Promote selection and concentration, create high-value-added products and services, and transform the company into a more highly profitable business. Under these management policies, the group actively pursued research and new product development in the 3 core areas and the development of new markets.」

「The group launched a new 3-year medium-term management plan in April 2018. …Under this management policy, it actively pursued research and new product development in 3 core areas.」

「The company will also link further research into functionality to product development and develop highly profitable new markets in Japan.」

「Under this corporate vision, the group worked to provide products that create new value, pursue research and development in the health and beauty and regenerative medicine fields, explore new manufacturing methods, and strengthen competitiveness through optimised production and sales.」

「Under this corporate vision, the group actively promoted proposals for high-value-added products that address customer needs and worked to raise awareness, including by holding the Life Science Biomaterials Study Group for the second consecutive year.」

「Under this corporate vision, the group worked to strengthen competitiveness through cost reductions such as production efficiency improvements and through optimised production and sales, provide products that create new value, and pursue research and development in the health and beauty and regenerative medicine fields.」

「The company participated in a demonstration trial under the Cabinet Office’s ImPACT programme and verified the effects of collagen peptide intake on improving brain function. The results suggested that collagen peptides may improve the quality of nerve fibres in the brain and contribute to more efficient information transmission in the brain, and the company announced the findings in a news release.」

「Against this backdrop, the group formulated a medium-term management plan ending in the fiscal year ending March 2018 and pursued three strategic priorities: 1. developing high-value-added products; 2. optimising production and sales; and 3. strengthening the global management platform.」

「Going forward, the company will apply the technologies it has developed to pursue high-value-added products, including collagen peptides with strong biological regulatory functions, gelatin and collagen for regenerative medicine such as iPS cells, products for the active senior market, which is expected to expand, and high-performance resins in the adhesives business that contribute to the automation of customers’ manufacturing processes.」